Inhibition of ROCK2 impedes osteoclastogenesis through Src-Ca2+-NFATc1 signaling pathway and alleviates ovariectomy-induced bone loss
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116342 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Qin Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key …. Hauptthemen laut MEDLINE: rho-Associated Kinases, Osteogenesis, Osteoclasts, Osteoporosis. Die Arbeit nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoporosis is a metabolic bone disease, and fractures caused by severe osteoporosis can lead to permanent disabilities. Targeting over-activated osteoclasts has become a therapeutic strategy for osteoporosis. Selective oral Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor KD025 has been approved by FDA for treating chronic graft- versus -host disease (cGVHD) recently. ROCK2 inhibition by KD025 can treat collagen-induced arthritis in vivo by downregulating proinflammatory cytokine secretion, while the roles and mechanisms of ROCK2 in osteoporosis remain to be determined. Here, we found that ROCK2 expression in pre-osteoclastic cells was markedly upregulated in an OVX-induced osteoporosis mouse model. ROCK2 inhibition by its orally available selective inhibitor KD025 prevented OVX-induced bone loss in vivo. Mechanistically, ROCK2 pharmacological inhibition with KD025 or ROCK2-specific siRNA suppressed osteoclastogenesis, bone resorption and F-actin rings formation in bone marrow-derived macrophages (BMMs) via downregulating NF-κB/p38-c-Fos signaling, Src-Ca 2+ -NFATc1 pathway, and the expression of osteoclast-related genes such as Trap , Oscar . Meanwhile, ROCK2 inhibition by KD025 showed no significant effect on osteoblast differentiation in vitro . Furthermore, the inhibitory effect of KD025 on osteoclastogenesis and NFATc1-luc transcription in vitro was weakened after silencing ROCK2. In a translation study, KD025 remarkably inhibited pathological osteoclastogenesis and bone resorption function in CD14 + macrophages from patients with osteoporosis. Collectively, our findings identify ROCK2 as a promising target for osteoclast-mediated osteolysis and highlight the potential of KD025 as a therapeutic drug for osteoporosis and metastatic bone destruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, Q., Chen, J., Li, L., Chen, Z., Li, R., Zheng, J., Chen, Y., Wang, S., & Li, X. (2026). Inhibition of ROCK2 impedes osteoclastogenesis through Src-Ca2+-NFATc1 signaling pathway and alleviates ovariectomy-induced bone loss. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116342
Vancouver
Yang Q, Chen J, Li L, Chen Z, Li R, Zheng J, et al. Inhibition of ROCK2 impedes osteoclastogenesis through Src-Ca2+-NFATc1 signaling pathway and alleviates ovariectomy-induced bone loss. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116342
BibTeX
@article{Yang2026,
author = {Yang, Qin and Chen, Jianchao and Li, Lihong and Chen, Ziye and Li, Ruopeng and Zheng, Jiehuang and Chen, Yan and Wang, Song and Li, Xiaojuan},
title = {Inhibition of ROCK2 impedes osteoclastogenesis through Src-Ca2+-NFATc1 signaling pathway and alleviates ovariectomy-induced bone loss},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116342}
}
EUVIMED